Status: Recruiting
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Participants needed: 160
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ImmVira Pharma Co. LtdUpdated: Jul 23, 2025Locations: 2
Eligibility criteria
Male or female, aged ≥18 years at the time of signing the ICF. [+12]
Concurrent or prior history of muscle-invasive (muscularis propria) or metastati... [+27]